Back to top
more

Inogen (INGN)

(Delayed Data from NSDQ)

$12.51 USD

12.51
256,355

+0.29 (2.37%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $12.49 -0.02 (-0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Hologic Wins FDA Approval for Genius 3D Mammography Exam

Hologic, Inc. (HOLX) continues to expand its Breast and Skeletal Health business through innovation and product development.

    Zimmer Biomet Rides on Spine Business, Knee Challenges Stay

    On Jun 6, we issued an updated research report on Warsaw, IN-based Zimmer Biomet Holdings Inc. (ZBH).

      Bruker Grows on NMR & Nano Businesses amid Several Odds

      On Jun 6, we issued an updated research report on Billerica, MA-based Bruker Corporation (BRKR), a manufacturer of proprietary life science and materials research systems.

        Boston Scientific Wins CE Mark for Vercise Gevia DBS System (revised)

        Generally, DBS therapy is a surgical procedure of placing a device that stimulates specific areas in the brain using electrical signals.

          Cardiovascular Systems Innovation On Track, Competition Rife

          On Jun 6, we issued an updated research report on St. Paul, MN-based Cardiovascular Systems, Inc. (CSII).

            Here's Why You Should Bet on Humana (HUM) Stock Right Now

            Louisville-based Humana Inc. (HUM), one of the largest health care plan providers in the United States, has been an investor favorite, given its strong fundamentals

              Medtronic SureTune3 Obtains Health Canada License for DBS

              Medtronic plc (MDT) recently announced the receipt of Health Canada license for SureTune 3 software for deep brain stimulation (DBS).

                Boston Scientific Wins CE Mark for Vercise Gevia DBS System

                Boston Scientific Corporation (BSX) recently won CE mark for its Vercise Gevia Deep Brain Stimulation (DBS) System.

                  HealthEquity (HQY) Q1 Earnings and Revenues Beat Estimates

                  HealthEquity Inc (HQY) reported earnings of 19 cents per share in the first quarter of fiscal 2018, higher than the Zacks Consensus Estimate of 16 cents.

                    Amedisys (AMED) Prospects Impressive Amid Tough Competition

                    On Jun 5, we issued an updated research report on leading molecular diagnostic company, Amedisys, Inc. (AMED).

                      Abiomed (ABMD) at 52-Week High: What's Driving the Stock?

                      Share price of Abiomed, Inc. (ABMD), scaled a new 52-week high of $142.95 on Jun 5, eventually closing a bit lower at $141.81.

                        Cerner (CERN) to Develop Electronic Health Records System

                        Cerner Corp (CERN) recently announced that it has been chosen by the U.S. Department of Veterans Affairs to develop an electronic health record (EHR) system.

                          Edwards Lifesciences (EW) SAPIEN 3 THV Gets FDA Approval

                          Edwards Lifesciences Corporation (EW) recently announced the receipt of FDA approval for aortic and mitral valve-in-valve procedures using SAPIEN 3 transcatheter heart valve (THV).

                            Strength Seen in DexCom (DXCM): Stock Adds 5% in Session

                            DexCom, Inc. (DXCM) shares rose over 5% in the last trading session.

                              Tenet Healthcare Prices New Notes to Repay Existing Debts

                              Tenet Healthcare Corporation (THC) recently priced the previously announced private offering of newly issued notes.

                                QIAGEN Strengthens Cancer Research Foothold on New License

                                QIAGEN N.V. (QGEN) has received a worldwide license for biomarkers to be used in identifying patients who may have benefited from immune-oncology (I-O) therapies in cancer treatment.

                                  Myriad Genetics BRACAnalysis CDx in OlympiAD Results Positive

                                  Myriad Genetics, Inc. (MYGN), a leading molecular diagnostics and personalized medicine company recently unveiled positive data pertaining to its BRACAnalysis CDx test.

                                    Align Sets Up Manufacturing Center in China, Grows in APAC

                                    Align Technology (ALGN) has recently inaugurated a new Invisalign treatment planning facility in Chengdu, China.

                                      Inogen Secures New Direct-to-Consumer Business Facility

                                      Inogen, Inc. (INGN) announced that it has secured a new business facility in the Cleveland, OH area.

                                        Abbott Laboratories at 52-Week High on Product Line, Buyouts

                                        Share price of IL-based Abbott Laboratories (ABT) scaled a new 52-week high of $46.55 on Jun 2, eventually closing a bit lower at $46.50.

                                          QIAGEN & Bristol-Myers Squibb Partner on Cancer Research

                                          QIAGEN N.V. (QGEN) has made significant advancement in the field of cancer research through the use of its revolutionary next-generation sequencing (NGS) technology.

                                            Quintiles IMS Holdings (Q) Holds Secondary Offering (revised)

                                            Q held a secondary offering of 10.6m shares, of which they repurchased $300m worth.

                                              Mead Johnson's Shareholders Approve Reckitt Benckiser Deal

                                              Mead Johnson's (MJN) stockholders have okayed the impending merger with Reckitt Benckiser Group.

                                                Hill-Rom Holdings Hits 52-Week High on Solid Product Line

                                                Share price of Batesville, IN-based Hill-Rom Holdings, Inc. (HRC) scaled a new 52-week high of $78.51 on Jun 1.

                                                  The Cooper Companies (COO) Beats Earnings Estimates in Q2

                                                  The Cooper Companies Inc. (COO) reported adjusted earnings of $2.50 in second-quarter fiscal 2017, surpassing the Zacks Consensus Estimate by 25 cents and improving from $2.05 in the year-ago quarter.